問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Pediatrics

Division of Hematology & Oncology

更新時間：2023-09-19

林佩瑾Lin, Pei-Chin
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林佩瑾

List

20Cases

2021-08-01 - 2027-10-27

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-03-14 - 2025-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2019-09-01 - 2027-12-31

Phase III

PHASE 3, OPEN LABEL, SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF-06838435 (RAAV-SPARK100-HFIX-PADUA) IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B (FIX:C ≤ 2%) (BENEGENE-2)

  • Condition/Disease

    Hemophilia B

  • Test Drug

    PF-06838435

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

2016-05-02 - 2021-05-12

Phase III

A Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults who require regular red blood cell transfusions due to beta (β)-thalassemia

  • Condition/Disease

    beta (β)-thalassemia

  • Test Drug

    Luspatercept (ACE-536)

Participate Sites
5Sites

Terminated4Sites

彭慶添
China Medical University Hospital-Taipei

未分科

2016-05-04 - 2020-10-31

Phase II

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT TRIAL OF AC-201 CONTROLLED RELEASE TABLETS IN SUBJECTS WITH HEMOPHILIC ARTHROPATHY

  • Condition/Disease

    HEMOPHILIC ARTHROPATHY

  • Test Drug

    AC-201CR

Participate Sites
6Sites

Terminated5Sites

張家堯
Taipei Medical University Hospital

Division of Hematology & Oncology

邱世欣
Kaohsiung Municipal Gangshan Hospital

未分科

2014-04-30 - 2023-04-16

Phase III

Safety and Efficacy of nonacog beta pegol (N9-GP) in Previously Untreated Patients with Haemophilia B

  • Condition/Disease

    Haemophilia B

  • Test Drug

    N9-GP

Participate Sites
2Sites

Recruiting2Sites

2019-03-14 - 2025-06-30

Phase III

A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residual FVIII Levels <= 1 IU/dL Receiving Prophylactic FVIII Infusions

  • Condition/Disease

    Hemophilia A

  • Test Drug

    BMN 270

Participate Sites
5Sites

Terminated5Sites

2019-03-14 - 2019-09-25

Phase III

A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Hemophilia A Patients with Residual FVIII Levels <= 1 IU/dL Receiving Prophylactic FVIII Infusions

  • Condition/Disease

    Hemophilia A

  • Test Drug

    BMN 270

Participate Sites
5Sites

Terminated5Sites

2024-05-01 - 2039-02-01

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2021-08-01 - 2027-10-27

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB